Pharmacology

Action Mechanism of Action Reference
ANTISENSE INHIBITOR Major intermediate early region 2 mRNA antisense inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Cytomegalovirus Retinitis 2 D017726 ClinicalTrials

Cross References

Resources Reference
ChEMBL CHEMBL1201512
FDA SRS 3Z6W3S36X5
PubChem 71587550